Tocagen is a biotech company founded in 2007 with a mission to end cancer mortality. They are focused on developing first-in-class product candidates for cancer treatment using their cancer-selective gene therapy platform. Initially targeting patients with recurrent high-grade glioma (HGG), their product candidates aim to activate the patient's immune system against their own cancer from within.

At the heart of Tocagen's approach is their proprietary gene therapy platform that utilizes retroviral replicating vectors (RRVs) to selectively deliver therapeutic genes into the DNA of cancer cells. This innovative technology is designed to combat cancer without the autoimmune toxicities often associated with other treatments, minimizing side effects and preserving healthy tissue. Tocagen is a fully integrated global company, driven by a team of specialized medical professionals including nutritionists, osteopathic physicians, ENT specialists, and oncologists.

Through their patient-centered approach, Tocagen strives to provide hope, comfort, and improved outcomes for cancer patients. To learn more about Tocagen and their innovative cancer treatments, visit their website or contact their offices in San Diego, CA